13 research outputs found
Considérations sur quelques caractères ethniques et anthropologiques de la population du département du Rhône
No full textBouchereau . Considérations sur quelques caractères ethniques et anthropologiques de la population du département du Rhône. In: Bulletin de la Société d'anthropologie de Lyon, tome 24, 1905. pp. 95-103
Poterie gallo-romaine ornée d'un dessin représentant la lutte de Mercure et du, dieu Pan
No full text
Quelques caractères anthropométriques du type criminel en Auvergne et sa comparaison avec le type normal
No full textAn ethnography of performance-based literacy assessment and classroom instruction
No full textThis year-long ethnographic study provides an in-depth view of one primary classroom teacher's use of mandated performance- and classroom-based literacy assessment in a first-second grade classroom. By describing the district's literacy instruction and assessment policies, and by interviewing key district personnel, the researcher documented external influences upon the teacher's instruction and assessment.The teacher used the district mandated performance assessment tasks. However, the timing and content of the tasks did not inform her instruction. With the help of the Language Arts Resource Specialist, the teacher developed student-centered portfolios, which did inform her instruction, resulting in changes in how she taught different levels of readers in her class. The teacher's instruction of the low and average groups changed from being only teacher-directed instruction in ability groups, to including individual conferences. She changed her emphasis from decoding and comprehension questions to meaning construction, student selection of appropriate books, and student self-monitoring.This study suggests that if mandated performance-based literacy assessments are to inform instruction, then they must be student-centered literacy activities which are scheduled throughout the year. Whether such assessments can inform instruction at the same time that they provide accountability data for administrators, needs further investigation. The teacher's use of student-centered portfolios indicates that teachers do not have to be fully grounded in whole language or literature-based reading before they can use portfolios to inform their instruction.Made available in DSpace on 2011-05-07T14:09:14Z (GMT). No. of bitstreams: 2
license.txt: 4922 bytes, checksum: 910b249b4beec47e7ab768910c8f966f (MD5)
9702458.pdf: 9930207 bytes, checksum: bfe111295225cd7a13fba5f36c78c57a (MD5)
Previous issue date: 1996Item marked as restricted to the 'UIUC Users [automated]' Group (id=2) by Howard Ding ([email protected]) on 2011-05-07T15:03:32Z
Item is restricted indefinitely.Restriction data tranferred 2014-07-01T11:30:17-05:00
Original Data
Group with Access UIUC Users [automated]
Release Date: none
Reason: ETDs are only available to UIUC Users without author permissionETDs are only available to UIUC Users without author permissionU of I Onl
Correction to: Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort (Critical Care, (2021), 25, 1, (177), 10.1186/s13054-021-03588-4)
No full textFollowing publication of the original article [1], the authors identified an error in the Abstract and Results section. The correct numbers and text are given hereafter. Abstract VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 group (adjusted HR 1.65 (95% CI 1.11–2.46), p = 0.013), but not in influenza (1.74 (0.99–3.06), p = 0.052), or no viral infection groups (1.13 (0.68–1.86), p = 0.63). Results Primary and secondary outcomes: VAP was associated with higher risk for 28-day mortality in in SARS-CoV-2 group, but not in the two other groups (Fig. 2A). All the changes that were requested are implemented in this correction and the original article [1] has been corrected. © The Author(s) 202
Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study
No full textBackground: Ventilator-associated pneumonia (VAP) is common in patients with severe SARS-CoV-2 pneumonia. The aim of this ancillary analysis of the coVAPid multicenter observational retrospective study is to assess the relationship between adjuvant corticosteroid use and the incidence of VAP. Methods: Planned ancillary analysis of a multicenter retrospective European cohort in 36 ICUs. Adult patients receiving invasive mechanical ventilation for more than 48 h for SARS-CoV-2 pneumonia were consecutively included between February and May 2020. VAP diagnosis required strict definition with clinical, radiological and quantitative microbiological confirmation. We assessed the association of VAP with corticosteroid treatment using univariate and multivariate cause-specific Cox’s proportional hazard models with adjustment on pre-specified confounders. Results: Among the 545 included patients, 191 (35%) received corticosteroids. The proportional hazard assumption for the effect of corticosteroids on the incidence of VAP could not be accepted, indicating that this effect varied during ICU stay. We found a non-significant lower risk of VAP for corticosteroid-treated patients during the first days in the ICU and an increased risk for longer ICU stay. By modeling the effect of corticosteroids with time-dependent coefficients, the association between corticosteroids and the incidence of VAP was not significant (overall effect p = 0.082), with time-dependent hazard ratios (95% confidence interval) of 0.47 (0.17–1.31) at day 2, 0.95 (0.63–1.42) at day 7, 1.48 (1.01–2.16) at day 14 and 1.94 (1.09–3.46) at day 21. Conclusions: No significant association was found between adjuvant corticosteroid treatment and the incidence of VAP, although a time-varying effect of corticosteroids was identified along the 28-day follow-up. © 2022, The Author(s)
Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort
No full textBackground: Patients with SARS-CoV-2 infection are at higher risk for ventilator-associated pneumonia (VAP). No study has evaluated the relationship between VAP and mortality in this population, or compared this relationship between SARS-CoV-2 patients and other populations. The main objective of our study was to determine the relationship between VAP and mortality in SARS-CoV-2 patients. Methods: Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox’s regression models, with cause-specific hazard for duration of mechanical ventilation and ICU stay, were used to compare outcomes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortality as competing event. Findings: Of 1576 included patients, 568 were SARS-CoV-2 pneumonia, 482 influenza pneumonia, and 526 no evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 (adjusted HR 1.70 (95% CI 1.16–2.47), p = 0.006), and influenza groups (1.75 (1.03–3.02), p = 0.045), but not in the no viral infection group (1.07 (0.64–1.78), p = 0.79). VAP was associated with significantly longer duration of mechanical ventilation in the SARS-CoV-2 group, but not in the influenza or no viral infection groups. VAP was associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was not different between study groups. Interpretation: VAP was associated with significantly increased 28-day mortality rate in SARS-CoV-2 patients. However, SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify the relationship between VAP and 28-day mortality. Clinical trial registration: The study was registered at ClinicalTrials.gov, number NCT04359693. © 2021, The Author(s)
